通过动态表型分析构建CARDS框架
本文指出部分符合柏林定义的COVID-19相关ARDS患者对当前治疗范式反应不佳,认为Rello等关于COVID-19表型的观点与Bos等的社论颇具价值,并建议通过重新评估难治性低氧的现有文献来加速推进Bos等推荐的COVID-19 ARDS(CARDS)«负责任»表型分析。
要点
- 部分符合柏林定义的COVID-19 ARDS患者对当前治疗反应不佳。
- 需结合临床、病理生理与免疫表型优化COVID-19管理。
- 重新评估难治性低氧现有文献可加速CARDS表型分析。
核心结论
- 部分符合柏林定义的COVID-19 ARDS患者对当前治疗范式反应不佳,需通过表型分析优化管理。
主要发现
- 部分COVID-19患者虽符合柏林ARDS标准,但对当前治疗范式反应不佳。
临床怎么用
- 可重新评估难治性低氧的现有文献以加速推进COVID-19 ARDS的«负责任»表型分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Using clinical, pathophysiological and immunological phenotyping of ARDS to refine management of COVID-19 is urgently required to improve outcomes from refractory hypoxia https://bit.ly/2VvZe1p Some patients with coronavirus disease 2019 (COVID-19), fulfilling the Berlin criteria for acute respiratory distress syndrome (ARDS), do not respond well to the current treatment paradigm [1]. The perspective by Rello et al. [2] on phenotypes of COVID-19, and the editorial by Bos et al. [3], are therefore of great interest. The “responsible” phenotyping of COVID-19 ARDS (CARDS) recommended by Bos et al. [3] may be expedited by re-evaluating the existing literature on refractory hypoxia.
引用
- Rajendram R. Building the house of CARDS by phenotyping on the fly. Eur Respir J. 2020. PMID: 32616600. doi:10.1183/13993003.02429-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。